Isolation from family and loved ones, along with a forced split from routines and support systems, was part of life for everyone during the height of the COVID-19 pandemic — but those changes fell especially hard on the disability community.
UW–Madison’s Karla Ausderau, an assistant professor in the School of Education’s Department of Kinesiology, has been awarded a COVID-19 Response Research and Education Award from the Wisconsin Partnership Program (WPP) at the UW–Madison School of Medicine and Public Health.
Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
For a patient suffering from a life-threatening illness like COVID-19, communication means everything. If that person is on a ventilator and no visitors are allowed in the room, doctors and nurses must rely on tools …